Search research articles
Contact Us
Filters
Showing results (101-110 of 138) with videos related to
Page
of 14
Sort By:
Advances in Therapy
|
August 28, 2024
The Impact of Psoriasis Treatments on the Risk of Skin Cancer: A Narrative Review
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, et al.
Expert Opinion on Drug Safety
|
May 3, 2024
Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, et al.
Biomedicines
|
October 23, 2021
New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?
Matteo Megna, Sonia Sofia Ocampo-Garza, Luca Potestio, et al.
Clinical, Cosmetic and Investigational Dermatology
|
December 26, 2022
The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review
Angelo Ruggiero, Fabrizio Martora, Gabriella Fabbrocini, et al.
Expert Opinion on Drug Safety
|
June 16, 2023
Efficacy and safety of sonidegib for the management of basal cell carcinoma: a drug safety evaluation
Alessia Villani, Massimiliano Scalvenzi, Giuseppe Micali, et al.
Frontiers in Endocrinology
|
March 27, 2026
The night matters: sleep quality and evening chronotype associated with clinical severity of psoriasis
Ludovica Verde, Martina Galasso, Giuseppe Annunziata, et al.
Dermatology and Therapy
|
October 8, 2025
Dermatologic Comorbidities Associated with Atopic Dermatitis Towards a Shared Therapeutical Approach: A Narrative Review
Maria Esposito, Alessandro Giunta, Andrea De Berardinis, et al.
Psoriasis (Auckland, N.Z.)
|
July 18, 2022
Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study
Matteo Megna, Luigi Fornaro, Luca Potestio, et al.
Dermatology Practical & Conceptual
|
August 9, 2023
Development of a Patient-Reported Outcome Measure (PROM) for Dysgeusia During Treatment With Smoothened (SMO) Inhibitors for Basal Cell Carcinomas: The SMO-iD Questionnaire
Elisa Camela, Alessia Villani, Sonia Sofia Ocampo Garza, et al.
Expert Opinion on Biological Therapy
|
June 16, 2025
Biologics targeting IL-23 in moderate-to-severe psoriasis: lessons learned from real-world use
Matteo Megna, Giuseppe Lauletta, Michela D'Agostino, et al.
Page
of 14
Search research articles
Search
Showing results (101-110 of 138) with videos related to
Sort By:
Page
of 14
Advances in Therapy
|
August 28, 2024
The Impact of Psoriasis Treatments on the Risk of Skin Cancer: A Narrative Review
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, et al.
Expert Opinion on Drug Safety
|
May 3, 2024
Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, et al.
Biomedicines
|
October 23, 2021
New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?
Matteo Megna, Sonia Sofia Ocampo-Garza, Luca Potestio, et al.
Clinical, Cosmetic and Investigational Dermatology
|
December 26, 2022
The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review
Angelo Ruggiero, Fabrizio Martora, Gabriella Fabbrocini, et al.
Expert Opinion on Drug Safety
|
June 16, 2023
Efficacy and safety of sonidegib for the management of basal cell carcinoma: a drug safety evaluation
Alessia Villani, Massimiliano Scalvenzi, Giuseppe Micali, et al.
Frontiers in Endocrinology
|
March 27, 2026
The night matters: sleep quality and evening chronotype associated with clinical severity of psoriasis
Ludovica Verde, Martina Galasso, Giuseppe Annunziata, et al.
Dermatology and Therapy
|
October 8, 2025
Dermatologic Comorbidities Associated with Atopic Dermatitis Towards a Shared Therapeutical Approach: A Narrative Review
Maria Esposito, Alessandro Giunta, Andrea De Berardinis, et al.
Psoriasis (Auckland, N.Z.)
|
July 18, 2022
Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study
Matteo Megna, Luigi Fornaro, Luca Potestio, et al.
Dermatology Practical & Conceptual
|
August 9, 2023
Development of a Patient-Reported Outcome Measure (PROM) for Dysgeusia During Treatment With Smoothened (SMO) Inhibitors for Basal Cell Carcinomas: The SMO-iD Questionnaire
Elisa Camela, Alessia Villani, Sonia Sofia Ocampo Garza, et al.
Expert Opinion on Biological Therapy
|
June 16, 2025
Biologics targeting IL-23 in moderate-to-severe psoriasis: lessons learned from real-world use
Matteo Megna, Giuseppe Lauletta, Michela D'Agostino, et al.
Page
of 14